Related references
Note: Only part of the references are listed.Sensitivity and specificity of surveillance case definitions in detection of influenza and respiratory syncytial virus among hospitalized patients, New Zealand, 2012-2016
William Davis et al.
JOURNAL OF INFECTION (2022)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis
You Li et al.
LANCET (2022)
Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus
Joseph A. Lewnard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study
Frederic Debellut et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Recommendations for respiratory syncytial virus surveillance at the national level
Anne C. Teirlinck et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study
You Li et al.
LANCET INFECTIOUS DISEASES (2021)
COVID-19 Lesson for Respiratory Syncytial Virus (RSV): Hygiene Works
Andrea Gastaldi et al.
CHILDREN-BASEL (2021)
Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model
Ranju Baral et al.
BMJ OPEN (2021)
Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review
Alex Mezei et al.
EPIDEMICS (2021)
Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance
Wei Cai et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2020)
Clinical characteristics, predictors, and performance of case definition-Interim results from the WHO global respiratory syncytial virus surveillance pilot
Siddhivinayak Hirve et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2020)
Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries
Xiao Li et al.
BMC MEDICINE (2020)
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
M. Pamela Griffin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models
Ranju Baral et al.
VACCINE (2020)
Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016
Birgitte K. Giersing et al.
VACCINE (2019)
Performance of Surveillance Case Definitions in Detecting Respiratory Syncytial Virus Infection Among Young Children Hospitalized With Severe Respiratory Illness-South Africa, 2009-2014
Brian Rha et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2019)
Global Review of the Age Distribution of Rotavirus Disease in Children Aged <5 Years Before the Introduction of Rotavirus Vaccination
Mateusz Hasso-Agopsowicz et al.
CLINICAL INFECTIOUS DISEASES (2019)
Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials
Andrew Clark et al.
LANCET INFECTIOUS DISEASES (2019)
Guidelines for multi-model comparisons of the impact of infectious disease interventions
Saskia den Boon et al.
BMC MEDICINE (2019)
Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis
You Li et al.
LANCET GLOBAL HEALTH (2019)
Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules
Andrew Clark et al.
LANCET GLOBAL HEALTH (2019)
Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study
Frederic Debellut et al.
LANCET GLOBAL HEALTH (2019)
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies
Ashley A. Leech et al.
VALUE IN HEALTH (2018)
Influenza interaction with cocirculating pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role for mathematical modelling
Lulla Opatowski et al.
PLOS PATHOGENS (2018)
Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data
Jessica Ochalek et al.
BMJ GLOBAL HEALTH (2018)
RSV associated hospitalizations in children in Karachi, Pakistan: Implications for vaccine prevention strategies
Asad Ali et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
Ting Shi et al.
LANCET (2017)
Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach
Wirichada Pan-Ngum et al.
VACCINE (2017)
Respiratory syncytial and influenza viruses in children under 2 years old with severe acute respiratory infection (SARI) in Maputo, 2015
Mirela Pale et al.
PLOS ONE (2017)
Evaluation of case definitions to detect respiratory syncytial virus infection in hospitalized children below 5 years in Rural Western Kenya, 2009-2013
Bryan O. Nyawanda et al.
BMC INFECTIOUS DISEASES (2016)
Cost-effectiveness thresholds: pros and cons
Melanie Y. Bertram et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2016)
Stillbirths: rates, risk factors, and acceleration towards 2030
Joy E. Lawn et al.
LANCET (2016)
WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015
Kayvon Modjarrad et al.
VACCINE (2016)
Cost of management of severe pneumonia in young children: systematic analysis
Shanshan Zhang et al.
JOURNAL OF GLOBAL HEALTH (2016)
The ProVac initiative and evolving decision support
Colin F. B. Sanderson
VACCINE (2015)
The changing landscape of respiratory syncytial virus
Fernando P. Polack
VACCINE (2015)
Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil
Hillegonda Maria Dutilh Novaes et al.
VACCINE (2015)
ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions
Barbara Jauregui et al.
VACCINE (2015)
Disability weights for the Global Burden of Disease 2013 study
Joshua A. Salomon et al.
LANCET GLOBAL HEALTH (2015)
Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines
A. T. Newall et al.
PHARMACOECONOMICS (2014)
Essential medicines for COPD and asthma in low and middle-income countries
Yaser T. Bazargani et al.
THORAX (2014)
Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants
Maarten O. Blanken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination
Andrew Clark et al.
VACCINE (2013)
Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma
Jean Bousquet et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data
Andrew Clark et al.
LANCET (2009)
Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi district, Kenya
D. James Nokes et al.
CLINICAL INFECTIOUS DISEASES (2008)
Share Paper
